The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
* This Week in the Journal
 June 15, 2006
 Audio Icon Audio Summary
*
Correspondence
* Depression — Augmentation or Switch after Initial SSRI Treatment
* Invariant Natural Killer T Cells in Bronchial Asthma
* ACAT Inhibition and the Progression of Coronary Atherosclerosis
* Who Is at Greatest Risk for Receiving Poor-Quality Health Care?
* HER2 Mutation and Response to Trastuzumab Therapy in Non–Small-Cell Lung Cancer
* Doxycycline Treatment for Lymphangioleiomyomatosis with Urinary Monitoring for MMPs
* Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia
*
Book Reviews
* Parasitic Diseases
* Phages: Their Role in Bacterial Pathogenesis and Biotechnology
* The Abnormal Menstrual Cycle
* Kidney Diseases in the Developing World and Ethnic Minorities
Original Articles
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Mutations in the kinase-binding domain of the BCR-ABL gene cause resistance to the BCR-ABL tyrosine kinase inhibitor imatinib in chronic myelogenous leukemia. This study found that dasatinib, a BCR-ABL inhibitor that targets most imatinib-resistant BCR-ABL mutations, has efficacy in imatinib-resistant chronic myelogenous leukemia or Philadelphia chromosome–positive acute lymphoid leukemia.

Related Editorial


Original Articles
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

This phase 1 study treated 119 patients with imatinib-resistant chronic myelogenous leukemia (CML) with nilotinib, an inhibitor of BCR-ABL tyrosine kinase. The drug had a relatively favorable safety profile and was active in patients who were in the blastic or accelerated phases of CML and in the chronic phase of CML with resistance to imatinib.

Related Editorial


Original Articles
Retinol-Binding Protein 4 and Insulin Resistance

In this study, serum levels of retinol-binding protein 4, a molecule secreted by adipocytes, correlated with the magnitude of insulin resistance in subjects with obesity, impaired glucose tolerance, or type 2 diabetes and in nonobese, nondiabetic subjects with a strong family history of type 2 diabetes. Levels of this molecule appear to be elevated in serum before the development of frank diabetes and might be used to identify insulin resistance and associated cardiovascular risk factors.

Related Editorial


Original Articles
Comparison of Two Fluid-Management Strategies in Acute Lung Injury

One of the characteristics of acute lung injury is noncardiogenic pulmonary edema. Arguments have been made for the management of acute lung injury with either a liberal or conservative approach to fluid administration. In this trial, neither approach offered a mortality benefit; there were clinical and physiological benefits to conservative fluid management.

Related Editorial


Clinical Practice
Idiopathic Short Stature

A healthy, active 12-year-old boy is in the first percentile for height (133.0 cm [52.4 in.]; –2.25 SD) and the third percentile for weight (29 kg [64 lb]). His physical examination is unremarkable, with normal proportions and no signs of puberty. His bone age is 10 years. His midparental height is 164.5 cm (64.8 in.), and his predicted height is 163.8 cm (64.5 in.). Is growth hormone therapy indicated?


Case Records of the Massachusetts General Hospital
A Woman with Numbness and Weakness of the Feet and Legs

A 57-year-old woman had had progressive numbness and weakness of the feet and legs since her early 30s. She had had dilated, fixed, and unequal pupils since adolescence. Her father had similar symptoms with his feet and legs, as well as dilated pupils and impotence. Two of her brothers, her son, and her daughter had neuropathy, dilated pupils, or both. A diagnostic procedure was performed.


Health Policy Reports
Obesity — The New Frontier of Public Health Law

The growing prevalence of obesity among adults and children has prompted legal initiatives designed to combat this public health problem. The authors describe litigation and legislation that target obesity and discuss the potential for public health law to reduce obesity in the United States.

Related Perspective


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.